Sign in
CompletedPhase 3

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Key facts

Who runs it
GenSight Biologics
Where
Atlanta, Aurora, Boston, Nashville, New York, Pasadena, and Philadelphia, United StatesSee the 7 sitesAlso in 6 other countries, 6 sites
Status
Completed
Phase
Phase 3
People taking part
98 people enrolled
Started
12 Mar 2018
Ended
23 Jul 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GS010
  • Placebo
Record updated
16 April 2026

Who can take part

Age
15 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Other criteria

  • Main Selection Criteria:
  • Age 15 years or older on the date of signed informed consent
  • Clinically manifested vision loss due to ND4 LHON, to any extent, in at least one eye
  • Vision loss duration of ≤ 365 days (i.e. ≤ 1 year) in each affected eye at Inclusion Visit (Visit 2); Main Non-Selection Criteria:
  • Contraindication to intravitreal injection in any eye
  • Subjects refusing to discontinue idebenone
  • Previous vitrectomy in either eye
  • Narrow angle in any eye contra-indicating pupillary dilation
  • Presence of known/documented mutations, other than the G11778A ND4 LHON-causing mutation, which are known to cause pathology of the optic nerve, retina or afferent visual system
  • History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation; Main Inclusion Criteria:
  • Vision loss duration of ≤ 365 days (i.e. ≤ 1 year) in each affected eye at Inclusion Visit (Visit 2)
  • Each eye of the subject must maintain at least Hand Motion (HM) visual acuity, as defined by the study's SOP for visual acuity testing
  • Documented results of genotyping showing the presence of the G11778A mutation in the ND4 gene and the absence of the other primary LHON-associated mutations (ND1 or ND6) in the subject's mitochondrial DNA; Main Exclusion Criteria:
  • Light Perception (LP) or No Light Perception (NLP) visual acuity in any eye, as defined by the study's standard operating procedure (SOP) for visual acuity testing
  • Presence of active infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye
  • Presence of alcoholism, alcohol dependence, or alcohol or drug abuse (excluding nicotine)

Where in United States

Also in 6 other countries, 6 sites

  • Emory Healthcare - The Emory ClinicAtlanta, United States
  • University of Colorado Health Eye CenterAurora, United States
  • Massachusetts Eye and Ear InfirmaryBoston, United States
  • Vanderbilt Eye InstituteNashville, United States
  • Department of Ophthalmology, Icahn School of Medicine at Mount SinaiNew York, United States
  • Doheny Eye Center UCLA PasadenaPasadena, United States
  • Departments of Neurology and Ophthalmology, Wills Eye Hospital and Thomas Jefferson UniversityPhiladelphia, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.

The 2 groups in the trial

  • GS010-GS010Treatment being tested

    Patients received single IVT injection of GS010 in both their first-affected eye and their second-affected/not-yet-affected eye at a droplet digital polymerase chain reaction (ddPCR) dose of 1.2/1.3E11 vg in 90 μL for each eye. Treatment could be performed either on a single day (1 IVT injection in each eye on Day 0) or on 2 consecutive days (1st IVT injection on Day -1 and 2nd IVT injection on Day 0).

    Treatment: GS010

  • GS010-PlaceboPlacebo, for comparison

    Patients received single IVT injection of GS010 in their first-affected eye and placebo IVT injection in their second-affected/not-yet-affected eye. Patients received IVT lenadogene nolparvovec in their first-affected eye (ddPCR dose of 1.2/1.3E11 vg in a volume of 90 μL) and placebo IVT injection (volume of 90 μL) in their second-affected/not-yet-affected eye. Treatment could be performed either on a single day (1 IVT injection in each eye on Day 0) or on 2 consecutive days (1st IVT injection on Day -1 and 2nd IVT injection on Day 0).

    Treatment: GS010 and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Publications
Record updated
16 April 2026